J
José Francisco Díaz Fernández
Publications - 49
Citations - 957
José Francisco Díaz Fernández is an academic researcher. The author has contributed to research in topics: Percutaneous coronary intervention & Acute coronary syndrome. The author has an hindex of 9, co-authored 39 publications receiving 684 citations.
Papers
More filters
Journal ArticleDOI
Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial
Olivier Varenne,Stéphane Cook,Georgios Sideris,Sasko Kedev,Thomas Cuisset,Didier Carrié,Thomas Hovasse,Philippe Garot,Rami El Mahmoud,Christian Spaulding,Gérard Helft,José Francisco Díaz Fernández,Salvatore Brugaletta,Eduardo Pinar-Bermudez,Josepa Mauri Ferre,Philippe Commeau,Emmanuel Teiger,Kris Bogaerts,Kris Bogaerts,Manel Sabaté,Marie-Claude Morice,Peter Sinnaeve +21 more
TL;DR: Among elderly patients who have PCI, a DES and a short duration of DAPT are better than BMS and a similar duration ofDAPT with respect to the occurrence of all-cause mortality, myocardial infarction, stroke, and ischaemia-driven target lesion revascularisation.
Journal ArticleDOI
Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial
Marco Valgimigli,Enrico Frigoli,Sergio Leonardi,Pascal Vranckx,Martina Rothenbühler,Matteo Tebaldi,Ferdinando Varbella,Paolo Calabrò,Stefano Garducci,Paolo Rubartelli,Carlo Briguori,Giuseppe Andò,Maurizio Ferrario,Ugo Limbruno,Roberto Garbo,Paolo Sganzerla,Filippo Russo,Marco Stefano Nazzaro,Alessandro Lupi,Bernardo Cortese,Arturo Ausiello,Salvatore Ierna,Giovanni Esposito,Giuseppe Ferrante,Andrea Santarelli,Gennaro Sardella,Nicoletta De Cesare,Paolo Tosi,Arnoud W J van 't Hof,Elmir Omerovic,Salvatore Brugaletta,Stephan Windecker,Dik Heg,Peter Jüni,Gianluca Campo,Lucia Uguccioni,Corrado Tamburino,Patrizia Presbitero,Dennis Zavalloni-Parenti,Fabio Ferrari,Roberto Ceravolo,Fabio Tarantino,Giampaolo Pasquetto,Gavino Casu,Stefano Mameli,Maria Letizia Stochino,Pietro Mazzarotto,Alberto Cremonesi,Francesco Saia,Giovanni Saccone,Fabio Abate,Andrea Picchi,Roberto Violini,Salvatore Colangelo,Giacomo Boccuzzi,Vincenzo Guiducci,Carlo Vigna,Antonio Zingarelli,Andrea Gagnor,Tiziana Zaro,Simone Tresoldi,Pietro Vandoni,Marco Contarini,Armando Liso,Dellavalle A,Salvatore Curello,Fabio Mangiacapra,Rosario Evola,Cataldo Palmieri,Camillo Falcone,Francesco Liistro,Manuela Creaco,Antonio Colombo,Alaide Chieffo,Andrea Perkan,Stefano De Servi,Dionigi Fischetti,Stefano Rigattieri,Alessandro Sciahbasi,Edoardo Pucci,Enrico Romagnoli,Claudio Moretti,Luciano Moretti,Raffaele De Caterina,Marcello Caputo,Marco Zimmarino,Ezio Bramucci,Emilio Di Lorenzo,Maurizio Turturo,Roberto Bonmassari,Carlo Penzo,Bruno Loi,Ciro Mauro,Anna Sonia Petronio,Gabriele Gabrielli,Antonio Micari,Flavia Belloni,Francesco Amico,Marco Comeglio,Claudio Fresco,Isala Klinieken,Nicolas M. Van Mieghem,Roberto Diletti,Evelyn Regar,Manel Sabaté,José Francisco Díaz Fernández,Vicente Mainar,José M. de la Torre Hernández +107 more
TL;DR: The prespecified final 1-year outcomes of the MATRIX programme, designed to assess the comparative safety and effectiveness of radial versus femoral access and of bivalirudin versus unfractionated heparin with optional glycoprotein IIb/IIIa inhibitors in patients with the whole spectrum of acute coronary syndrome undergoing invasive management, are described.
Journal ArticleDOI
Primary angioplasty vs. fibrinolysis in very old patients with acute myocardial infarction: TRIANA (TRatamiento del Infarto Agudo de miocardio eN Ancianos) randomized trial and pooled analysis with previous studies.
Héctor Bueno,Amadeo Betriu,Magda Heras,Joaquín Alonso,Angel Cequier,Eulogio García,Jose Lopez-Sendon,Carlos Macaya,Rosana Hernández-Antolín,José Azpitarte,Ginés Sanz,Angel Chamorro,Ramón López-Palop,Alex Sionis,Fernando Arós,Eulogio García-Fernández,Rafael Rubio,Felipe Hernández,Juan Carlos Tascón,José Moreu,Amadeu Betriu,Antonio Fernández-Ortiz,César Morís,Ignacio Sánchez de Posada,Enrique Esplugas,Rafael Melgares,Francisco Bosa,Martín Jesús García-González,Román Lezaún,José Ramón Carmona,José Manuel Vázquez,Alfonso Castro-Beiras,Joan García Picart,José Domínguez de Rozas,José Francisco Díaz Fernández,Felipe Fernández Vázquez,Norberto Alonso,José Javier Zueco,José María San José,Alberto San Román,Carolina Hernández,José María Hernández García,Ángel García Alcántara,Armando Bethencourt,Miquel Fiol,Xabier Mancisidor,Rafael Ruiz,Rafael Hidalgo,Nicolás Sobrino,Isidoro González Maqueda,Alfonso Torres,Antonio Amaro,Michel Jaquet +52 more
TL;DR: Primary PCI seems to be the best reperfusion therapy for STEMI even for the oldest patients, and early contemporary fibrinolytic therapy may be a safe alternative to pPCI in the elderly when this is not available.
Journal ArticleDOI
A prospective randomized trial of everolimus-eluting stents versus bare-metal stents in octogenarians: the XIMA Trial (Xience or Vision Stents for the Management of Angina in the Elderly).
Adam de de Belder,José M. de la Torre Hernández,Ramón López-Palop,Peter O'Kane,Felipe Hernández,Julian Strange,Federico Gimeno,James Cotton,José Francisco Díaz Fernández,Pilar Carrillo Sáez,Martyn Thomas,Eduardo Pinar,Nick Curzen,José Antonio Baz,Nina Cooter,Iñigo Lozano,Nicola Skipper,Derek R. Robinson,David Hildick-Smith,Xima Investigators +19 more
TL;DR: In this article, drug-eluting stents (DES) were compared to bare-metal stents in octogenarian patients with angina, and the results showed that DES was associated with a lower incidence of myocardial infarction and target vessel revascularization without increased incidence of major hemorrhage.
Journal ArticleDOI
Transcatheter Mitral Valve Repair in Cardiogenic Shock and Mitral Regurgitation: A Patient-Level, Multicenter Analysis.
Richard G. Jung,Trevor Simard,Christopher P. Kovach,Kelsey M. Flint,Creighton W. Don,Pietro Di Santo,Marianna Adamo,Luca Branca,Francesca Valentini,Tomás Benito-González,Felipe Fernández-Vázquez,Rodrigo Estévez-Loureiro,Alessandra Berardini,Nicolina Conti,Claudio Rapezzi,Elena Biagini,Simon Parlow,Risa Shorr,Amos Levi,Ana J. Manovel,Rosa Cardenal-Piris,José Francisco Díaz Fernández,Mony Shuvy,Dan Haberman,Alessandra Sala,Mohamad A. Alkhouli,Claudia Marini,Marta Bargagna,Davide Schiavi,Paolo Denti,Sinisa Markovic,Nicola Buzzatti,Vincent Chan,Mark Hynes,Thierry G. Mesana,Marino Labinaz,Federico Pappalardo,Maurizio Taramasso,Benjamin Hibbert +38 more
TL;DR: Transcatheter mitral valve repair may improve short- and intermediate-term mortality in high-risk patients with cardiogenic shock and moderate to severe MR and Randomized studies are needed to definitively establish MR as a therapeutic target.